Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Invest. 2013 Jan;31(1):24-38. doi: 10.3109/07357907.2012.743553. Epub 2012 Nov 29.

Inhibition of nuclear factor kappa B activation in early-stage chronic lymphocytic leukemia by omega-3 fatty acids.

Author information

1
Department of Biochemistry and Microbiology, Marshall University School of Medicine, Huntington,WV 25755, USA.

Abstract

Targeting the nuclear factor kappa B (NFκB) pathway is proposed as therapy for chronic lymphocytic leukemia (CLL). We hypothesized that an omega-3 fatty acids (n-3) supplement would suppress NFκB activation in lymphocytes of Rai Stage 0-1 CLL patients. The initial dose of 2.4 g n-3/day was gradually increased to 7.2 g n-3/day. After n-3 consumption: 1) plasma n-3 increased; 2) NFκB activation was suppressed in lymphocytes; 3) in vitro sensitivity of lymphocytes to doxorubicin was increased; and 4) expression of 32 genes in lymphocytes was significantly decreased.

PMID:
23193970
DOI:
10.3109/07357907.2012.743553
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center